• 1
    Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 1993; 53: 391924.
  • 2
    Hard GC, Iatropoulos MJ, Jordan K, Radi L, Kaltenberg OP, Imondi AR, Williams GM. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD (BR) rats. Cancer Res 1993; 53: 453441.
  • 3
    Hirsimäki P, Hirsimäki Y, Nieminen L, Payne BJ. Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens. Arch Toxicol 1993; 67: 4954.
  • 4
    Williams GM, Iatropoulos MJ, Djordjevic MV, Kaltenberg OP. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 1993; 14: 3157.
  • 5
    Jordan VC. The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole. Breast Cancer Res Treat 1988; 11: 197209.
  • 6
    Baum M, Brinkley DM, Dossett JA, Mcpherson K, Patterson JS, Rubens RD, Smiddy FG, Stoll BA, Wilson A, Richards D, Ellis SH. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Lancet 1985; 13: 83640.
  • 7
    Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 137188.
  • 8
    Mani C, Pearce R, Parkinson A, Kupfer D. Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis 1994; 15: 271520.
  • 9
    Pathak DN, Bodell WJ. DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis 1994; 15: 52932.
  • 10
    Davies AM, Martin EA, Jones RM, Lim CK, Smith LL, White IN. Peroxidase activation of tamoxifen and toremifene resulting in DNA damage and covalently bound protein adducts. Carcinogenesis 1995; 16: 53945.
  • 11
    Pongracz K, Pathak DN, Nakamura T, Burlingame AL, Bodell WJ. Activation of the tamoxifen derivative metabolite E to form DNA adducts: comparison with the adducts formed by microsomal activation of tamoxifen. Cancer Res 1995; 55: 30125.
  • 12
    Pathak DN, Pongracz K, Bodell WJ. Microsomal and peroxidase activation of 4-hydroxy-tamoxifen to form DNA adducts: comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen. Carcinogenesis 1995; 16: 115.
  • 13
    White IN, De Matteis F, Gibbs AH, Lim CK, Wolf CR, Henderson C, Smith LL. Species differences in the covalent binding of [14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochem Pharmacol 1995; 49: 103542.
  • 14
    Phillips DH, Potter GA, Horton MN, Hewer A, Crofton-Sleigh C, Jarman M, Vennit S. Reduced genotoxicity of [D5-ethyl]tamoxifen implicates α-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis 1994; 15: 148792.
  • 15
    Phillips DH, Carmichael PL, Hewer A, Cole KJ, Poon GK. α-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res 1994; 54: 551822.
  • 16
    Potter GA, McCague R, Jarman M. A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis 1994; 15: 43942.
  • 17
    Phillips DH, Carmichael PL, Hewer A, Cole KJ, Hardcastle IR, Poon GK, Keogh A, Strain AJ. Activation of tamoxifen and its metabolite α-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes. Carcinogenesis 1996; 17: 8994.
  • 18
    Beland FA, McDaniel LP, Marques MM. Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo. Carcinogenesis 1999; 20: 4717.
  • 19
    da Costa GG, Marques MM, Beland FA, Freeman JP, Churchwell MI, Doerge DR. Quantification of tamoxifen DNA adducts using on-line sample preparation and HPLC-electrospray ionization tandem mass spectrometry. Chem Res Toxicol 2003; 16: 35766.
  • 20
    Shibutani S, Shaw PM, Suzuki N, Dasaradhi L, Duffel MW, Terashima I. Sulfation of α-hydroxytamoxifen catalyzed by human hydroxysteroid sul-fotransferase results in tamoxifen-DNA adducts. Carcinogenesis 1998; 19: 200711.
  • 21
    Glatt H, Davis W, Meinl W, Hermersdörfer H, Venitt S, Phillips, DH. Rat, but not human, sulfotransferase activates a tamoxifen metabolite to produce DNA adducts and gene mutations in bacteria and mammalian cells in culture. Carcinogenesis 1998; 19: 170913.
  • 22
    Umemoto A, Monden Y, Suwa M, Kanno Y, Suzuki M, Lin CX, Ueyama Y, Momen MA, Ravindernath A, Shibutani S, Komaki K. Identification of hepatic tamoxifen-DNA adducts in mice: α-(N2-deoxyguanosinyl)tamoxifen and α-(N2-deoxyguanosinyl)tamoxifen N- oxide. Carcinogenesis 2000; 21: 173744.
  • 23
    Kasahara T, Hashiba M, Harada T, Degawa M. Change in the gene expression of hepatic tamoxifen-metabolizing enzymes during the process of tamoxifen-induced hepatocarcinogenesis in female rats. Carcinogenesis 2002; 23: 4918.
  • 24
    Jin SG, Choi JH, Ahn B, O'Connor TR, Mar W, Lee CS. Excision repair of adozelesin-N3 adenine adduct by 3-methyladenine-DNA glycosylases and UvrABC nuclease. Mol Cells 2001; 11: 417.
  • 25
    Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 2002; 511: 14578.
  • 26
    Berg RJ, Rebel H, van der Horst GT, van Kranen HJ, Mullenders LH, van Volten WA, de Gruijl FR. Impact of global genome repair versus transcription-coupled repair on ultraviolet carcinogenesis in hairless mice. Cancer Res 2000; 60: 285863.
  • 27
    Wijnhoven SW, Kool HJ, Mullenders LH, Slater R, van Zeeland AA, Vrieling H. DMBA-induced toxic and mutagenic responses vary dramatically between NER-deficient Xpa, Xpc and Csb mice. Carcinogenesis 2001; 22: 1099106.
  • 28
    Dowty HV, Xue W, LaDow K, Talaska G, Warshawsky D. One-electron oxidation is not a major route of metabolic activation and DNA binding for the carcinogen 7H-dibenzo-[c, g]carbazole in vitro and in mouse liver and lung. Carcinogenesis 2000; 21: 9918.
  • 29
    Lin PH, Nakamura J, Yamaguchi S, La DK, Upton PB, Swenberg JA. Induction of direct adducts, apurinic/apyrimidinic sites and oxidized bases in nuclear DNA of human HeLa S3 tumor cells by tetrachlorohydroquinone. Carcinogenesis 2001; 22: 6359.
  • 30
    Tsurudome Y, Hirano T, Yamato H, Tanaka I, Sagai M, Hirano H, Nagata N, Itoh H, Kasai H. Changes in levels of 8-hydroxyguanine in DNA, its repair and OGG1 mRNA in rat lungs after intratracheal administration of diesel exhaust particles. Carcinogenesis 1999; 20: 15736.
  • 31
    Shibutani S, Reardon JT, Suzuki N, Sancar A. Excision of tamoxifen-DNA adducts by the human nucleotide excision repair system. Cancer Res 2000; 60: 260710.
  • 32
    Pascale RM, De Miglio MR, Muroni MR, Simile MM, Daino L, Seddaiu MA, Nufris A, Gaspa L, Deiana L, Feo F. c-myc amplification in pre-malignant and malignant lesions induced in rat liver by the resistant hepatocyte model. Int J Cancer 1996; 68: 13642.
  • 33
    Hsu JD, Hsu CL, Chou FP, Wen PH, Wang CJ. Potential effect of sodium nitrite on the expression of nuclear proto-oncogenes during 2-acetyl aminofluorene-induced hepatocarcinogenesis in rats. Chem Biol Interact 1997; 108: 118.
  • 34
    Henriksson M, Luscher B. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res 1996; 68: 10982.
  • 35
    Naitoh H, Shibata J, Kawaguchi A, Kodama M, Hattori T. Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am J Pathol 1995; 146: 11619.
  • 36
    McIntosh GG, Anderson JJ, Milton I, Steward M, Parr AH, Thomas MD, Henry JA, Angus B, Lennard TW, Horne CH. Determination of the prognostic value of cyclin D1 overexpresssion in breast cancer. Oncogene 1995; 11: 88591.
  • 37
    Nishida N, Fukuda Y, Komeda T, Kita R, Sando T, Furukawa M, Amenomori M, Shibagaki I, Nakao K, Ikenaga M, Ishizaki K. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res 1994; 54: 310710.
  • 38
    Betticher DC, Heighway J, Hasleton PS, Altermatt HJ, Ryder WD, Cerny T, Thatcher N. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer 1996; 73: 294300.
  • 39
    Kelman Z, Hurwitz J. Protein-PCNA interactions: a DNA-scanning mechanism Trends Biochem Sci 1998; 23: 2368.
  • 40
    Jonsson ZO, Hubscher U. Proliferating cell nuclear antigen: more than a clamp for DNA polymerases. Bioessays 1997; 19: 96775.
  • 41
    Gallant P, Nigg EA. Cyclin B2 undergoes cell cycle-dependent nuclear translocation and, when expressed as a non-destructible mutant, causes mitotic arrest in HeLa cells. J Cell Biol 1992; 117: 21324.
  • 42
    Okuda A, Sakai M, Muramatsu M. The structure of the rat glutathione S-transferase P gene and related pseudogenes. J Biol Chem 1987; 262: 385863.
  • 43
    Shibata K, Itoh M, Aizawa K, Nagaoka S, Sasaki N, Carninci P, Konno H, Akiyama J, Nishi K, Kitsunai T, Tashiro H, Itoh M, Sumi N, Ishii Y, Nakamura S, Hazama M, Nishine T, Harada A, Yamamoto R, Matsumoto H, Sakaguchi S, Ikegami T, Kashiwagi K, Fujiwake S, Inoue K, Togawa Y. RIKEN integrated sequence analysis (RISA) system-384-format sequencing pipeline with 384 multicapillary sequencer. Genome Res 2000; 10: 175771.
  • 44
    Li L, Peterson C, Legerski R. Sequence of the mouse XPC cDNA and genomic structure of the human XPC gene. Nucleic Acids Res 1996; 24: 10268.
  • 45
    Wilson TM, Rivkees SA, Deutsch WA, Kelley MR. Differential expression of the apurinic/apyrimidinic endonuclease (APE/ref-1) multifunctional DNA base excision repair gene during fetal development and in adult rat brain and testis. Mutat Res 1996; 362: 23748.
  • 46
    Potter JJ, Rennie-Tankersley L, Anania FA, Mezey E. A transient increase in c-myc precedes the transdifferentiation of hepatic stellate cells to myofibro blast-like cells. Liver 1999; 19: 13544.
  • 47
    Wang QS, Sabourin CL, Wang H, Stoner, GD. Overexpression of cyclin D1 and cyclin E in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis. Carcinogenesis 1996; 17: 15838.
  • 48
    Spiewak Rinaudo JA, Thorgeirsson SS. Detection of tyrosine-phosphorylated form of cyclin A during liver regeneration. Cell Growth Differ 1997; 8: 3019.
  • 49
    Graham RC, Karnovsky MJ. The early stages of adsorption of injected horseradish peroxidase in the proximal tubules of mouse kidney; ultrastructural cytochemistry by a new technique. J Histochem Cytochem 1966; 14: 291302.
  • 50
    Carthew P, Rich KJ, Martin EA, De Matteis F, Lim CK, Manson MM, Festing MF, White IN, Smith LL. DNA damage as assessed by 32P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumor formation. Carcinogenesis 1995; 16: 1299304.
  • 51
    Carthew P, Nolan BM, Edwards RE, Smith LL. The role of cell death and cell proliferation in the promotion of rat liver tumours by tamoxifen. Cancer Lett 1996; 106: 1639.
  • 52
    Karki A, Mantyla E, Hirsimaki Y, Karlsson S, Toikkanen S, Hirsimaki P. Comparison of the effects of tamoxifen and toremifene on rat hepatocarcinogenesis. Arch Toxicol 2000; 74: 24956.
  • 53
    Maiti S, Chen G. Tamoxifen induction of aryl sulfotransferase and hydroxysteroid sulfotransferase in male and female rat liver and intestine. Drug Metab Dispos 2003; 31: 63744.
  • 54
    Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Hjalmar ML. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 1: 11720.
  • 55
    Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1995; 87: 64551.
  • 56
    Shibutani S, Ravindernath A, Suzuki N, Terashima I, Sugarman SM, Grollman AP, Pearl ML. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 2000; 21: 14617.
  • 57
    White IN. The tamoxifen dilemma. Carcinogenesis 1999; 20: 115360.
  • 58
    Hukkanen J, Mantyla M, Kangas L, Wirta P, Hakkola J, Paakki P, Evisalmi S, Pelkonen O, Raunio H. Expression of cytochrome P450 genes encoding enzymes active in the metabolism of tamoxifen in human uterine endometrium. Pharmacol Toxicol 1998; 82: 937.